Perception Neuroscience is focused on advancing mental health treatment through the development of PCN-101, also known as Arketamine or R-ketamine. This innovative compound aims to offer enhanced solutions for individuals suffering from serious mental health disorders. The company is dedicated to changing the perception of mental health by providing effective therapeutic options that address the complexities of these conditions.

The research and development efforts at Perception Neuroscience emphasize the potential of PCN-101 to improve patient outcomes significantly. By leveraging the unique properties of Arketamine, the company seeks to create a more effective treatment paradigm for mental health disorders, moving beyond traditional approaches. Their commitment to scientific advancement and patient care positions them as a key player in the evolving landscape of mental health solutions.

United States

Perception Neuroscience is developing PCN-101 (Arketamine, or R-ketamine) with a vision of providing significantly improved solutions to serious mental health disorders.

Perception Neuroscience

Company Details